Trim 30-40% of SBUX long exposure via staged execution ($93.65 → $96.79-$97.47), preserve 60-70% residual for Japan-deal optionality and Q4 FY26 earnings; protective stop at $90.85.
Trim SBUX long exposure 30-40% via staged execution: initial 20% at market (~$93.65), conditional additional 10-20% on rallies into $96.79-$97.47 (10 EMA / 200 SMA confluence). Preserve 60-70% residual for Japan-deal optionality, Q4 FY26 binary convexity, and franchise-floor absorption. Bear-bias flip line at $103.46 close (50 SMA reclaim = underweight exit). Residual protective stop at $90.85 close (below lower Bollinger Band). No fresh shorts until $90.85 prints reversal failure per plan directive. Bear target $88-89 (2× ATR extension). Price target $88.5. Time horizon 6-9 months through Q4 FY26 earnings. The underweight rating is supported by three consecutive quarters of revenue decline ($9.92B → $9.53B → $9.32B), 400bps structural gross margin compression, normalized Q3 net income essentially flat sequentially despite headline 87% growth (flattered by $536M China JV one-time gain), negative book equity (-$7.67B), hostile macro (30x forward P/E vs 5% risk-free = -170bps real yield), and confirmed distribution regime (VWMA declining from ~$107 to ~$98).
| Position | Action |
|---|---|
| At market | Trim initial 20% of SBUX long exposure |
| On rallies into $96.79-$97.47 (10 EMA / 200 SMA confluence) | Trim conditional additional 10-20% of SBUX long exposure |
| Residual position maintenance | Preserve 60-70% residual for Japan-deal optionality, Q4 FY26 binary convexity, and franchise-floor absorption |
SBUX's oversold technical setup combined with record free cash flow generation, accelerating margin expansion, and disciplined capital allocation during its turnaround creates a compelling risk/reward at 30x forward earnings with catalysts on deck.
| Indicator | Value | Signal |
|---|---|---|
| close_10_ema | 96.79 | bearish |
| close_50_sma | 103.46 | bearish |
| close_200_sma | 97.47 | bearish |
| rsi | 25.04 | neutral |
| macd | -2.91 | bearish |
| macd_signal | -2.09 | bearish |
| macd_histogram | -0.82 | bearish |
| bollinger_middle | 101.06 | bearish |
| bollinger_upper | 111.27 | bearish |
| bollinger_lower | 90.85 | neutral |
| atr | 2.35 |
This report is AI-generated for informational and educational purposes only and is not investment advice or a recommendation to buy or sell any security. Full disclaimer.
When: Rallies into $96.79-$97.47 (10 EMA / 200 SMA confluence)
Then: Execute additional 10-20% trim of SBUX long exposure
↩ rebuts: “Bear's valuation complaint and macro-headline narrative”
EV: +5.7% to +15.7% ($108–115 target zone over 6–9 months) · concedes: The 10-year at 5% and 97% probability of no 2026 Fed cuts are headwinds for high-multiple growth stocks; The stock may stay flat for a few more weeks before a re-rating catalyst materializes
SBUX is a falling knife in a hawkish macro regime with company-specific catalysts deteriorating (China competitive position lost, two waves of restructuring, declining revenue), technical distribution confirmed, and premium multiples structurally compressing due to record-high yields—making SELL the appropriate recommendation.
· concedes: Zero retail posts across three major forums on a 13% drop with major restructuring announcement is unusual; FCF of $1.35B and dividend yield of 2.63% exist as cash return mechanisms; A close above $103.46 on rising volume AND positive MACD histogram turn would flip bearish bias; Q4 FY26 earnings showing both revenue stabilization AND like-for-like traffic improvement would shift fundamentals; 10-year yield rolling over below 4.5% would relieve multiple-compression pressure
→ vs conservative: RSI at 25 is not a buy signal in confirmed downtrends; buying oversold readings is how you catch a $96 stock to $88; the technical report itself flags this as 'knife-catching risk'
→ vs conservative: Negative book value of minus $7.67B is not just 'structural'—it means the company has returned more capital than earned over its modern history, constraining future buybacks
→ vs conservative: Waiting for stabilization signals like 10-year rollover before acting on stock that broke below all three major MAs is anchoring to hope, not discipline
→ vs neutral: Q3 FY26 'earnings beat' is largely an accounting event; normalized $509M net income is actually DOWN from Q2's $511M; Q3 margin expansion bought by one-time gain and diminishing cost cuts
→ vs neutral: Brian Niccol's pedigree doesn't overcome hostile macro regime; 10-year at 5% and 97% odds of no Fed cuts in 2026 is not a regime about to flip
→ vs neutral: Waiting for Q4 earnings clarity and bond market rollover before acting means missing the move after 10-15% more downside is realized
→ vs conservative: The 'already priced in bad news' argument at 13% drawdown is hindsight anchoring; haven't touched lower Bollinger Band at $90.85 yet
→ vs conservative: In confirmed distribution patterns with price below all major MAs and falling momentum, you don't wait for chart confirmation of what it's already screaming
| neutral |
| vwma_20day | 98.09 | bearish |
| close_price | 93.65 | bearish |
Support: 92.76 · 90.85 · 88 | Resistance: 96.79 · 97.47 · 101.06 · 103.46
SBUX exhibits a textbook bearish multi-timeframe alignment with price ($93.65) simultaneously below the 10 EMA ($96.79), 50 SMA ($103.46), and 200 SMA ($97.47). Momentum is oversold (RSI 25.04) but still deteriorating with MACD histogram negative at −0.82, while VWMA has declined from $106.81 to $98.09 confirming distribution bias. The decline from the Aug 26 peak of $108.49 represents approximately −13.7% in 21 trading days with persistent lower highs and lower lows; price has not yet touched the lower Bollinger Band ($90.85). The final transaction proposal is HOLD: existing positions should be maintained while awaiting either (a) a 10 EMA/200 SMA reclaim with positive MACD histogram for a buy setup, or (b) a lower-band touch with RSI capitulation for a defined-risk tactical short.
Market Cap
$106.76B
Current Price
$93.80
52-Week Range
$77.99 – $110.51
Beta
0.965
P/E (TTM)
54.1x
Forward P/E
30.0x
PEG Ratio
1.11
P/B
-13.9x
EV/EBITDA
~22.4x
Dividend Yield
2.63%
Revenue (TTM)
$38.34B
FY2025 Revenue
$37.18B
FY2024 Revenue
$36.18B
FY2023 Revenue
$35.98B
FY2022 Revenue
$32.25B
FY2021 Revenue
$29.06B
Revenue Growth YoY (FY2025)
+2.8%
Gross Margin
22.8%
Operating Margin
12.9%
Net Margin
5.2%
FY2025 Gross Margin
22.8%
FY2025 Operating Margin
9.6%
FY2024 Operating Margin
14.1%
FY2023 Operating Margin
15.3%
ROA
8.02%
EPS (TTM)
$1.73
EPS (Forward)
$3.12
FY2025 Diluted EPS
$1.63
FY2024 Diluted EPS
$3.31
FY2023 Diluted EPS
$3.58
FY2022 Diluted EPS
$2.83
FY2021 Diluted EPS
$3.54
FY2025 Net Income
$1.86B
FY2024 Net Income
$3.76B
FY2023 Net Income
$4.12B
FY2022 Net Income
$3.28B
FY2021 Net Income
$4.20B
Restructuring Charges (FY2025)
$892M
Cash & Equivalents
$3.45B
Total Debt
$22.43B
Net Debt
$9.83B
Stockholders' Equity
-$7.67B
Book Value Per Share
-$6.73
Current Ratio
0.76
Working Capital
-$2.38B
Goodwill
$1.24B
LTM Free Cash Flow
$3.07B
FY2025 Free Cash Flow
$2.44B
FY2024 Free Cash Flow
$3.32B
FY2023 Free Cash Flow
$3.68B
FY2022 Free Cash Flow
$2.56B
FCF Conversion (FY2025)
51%
CapEx (LTM)
~$1.34B
Dividends Paid (LTM)
~$2.81B
Dividends (Annual)
~$2.77B
Buybacks (FY25-26)
$0
China Sale Proceeds
$2.54B
Q3 FY26 Revenue
$9.32B
Q3 FY26 Operating Income
$1.204B
Q3 FY26 Net Income
$1.045B
Q3 FY26 EPS
$0.91
Q3 FY26 Operating Margin
13.1%
Q3 FY26 FCF
$1.35B
Q2 FY26 EPS
$0.45
Q1 FY26 EPS
$0.26
Interest Expense (Annual)
~$540M
U.S. Starbucks Rewards Members
34M+
Global Stores
~40,000+
50-Day Moving Average
$103.75
200-Day Moving Average
$98.39
FCF Yield
~2.9%
Strengths
Concerns
Starbucks is navigating a significant operational turnaround with Q3 FY26 showing strong recovery (EPS $0.91, +79% YoY) driven by the "Back to Starbucks" strategic reset and completed China JV divestiture. However, FY2025 was severely impacted by $892M restructuring charges and China impairments that compressed net income by ~50% to $1.86B, while revenue growth has decelerated from +11% to +2.8%. The balance sheet shows a structural weakness with negative stockholders' equity (-$7.67B) from historical buybacks, though aggressive deleveraging has reduced debt by $5.4B YoY and record Q3 FCF of $1.35B demonstrates strong cash generation capacity. The stock at ~$93.80 trades at a forward P/E of 30x on $3.12 EPS consensus, fairly valuing the recovery narrative with margin expansion to mid-teens the key catalyst for re-rating to $115-130.